



ASX Announcement

November 21, 2019

Results of Annual General Meeting

In accordance with Listing Rule 3.13.2, it is confirmed that the following resolutions put to the Annual General Meeting of Invex Therapeutics Ltd shareholders held on 21 November 2019 were unanimously passed on a show of hands:

- Resolution 1: Adoption of Remuneration Report
- Resolution 2: Election of Director – Professor Alexandra Sinclair
- Resolution 3: Election of Director – David McAuliffe
- Resolution 4: Election of Director – Dr Jason Loveridge
- Resolution 5: Election of Director – Narelle Warren
- Resolution 6: Issue of Incentive Options to Director – David McAuliffe
- Resolution 7: Issue of Incentive Options to Director – Dr Jason Loveridge
- Resolution 8: Issue of Incentive Options to Director – Narelle Warren
- Resolution 9: Issue of Incentive Options to Director – Professor Alexandra Sinclair
- Resolution 10: Approve appointment of auditor at first AGM
- Resolution 11: Approval of 10% Placement Capacity

Details of the instructions given to validly appointed proxies in respect of each resolution in accordance with section 251AA of the Corporations Act are set out in the attached proxy summary.

Yours faithfully

Narelle Warren
Company Secretary



Annual General Meeting – 21 November 2019

Voting Results

The following information is provided in accordance with section 251AA of the Corporations Act 2001.

Resolution	Decided on Show of Hands (S) or Poll (P)	Proxy Votes Received					
		For	Against	Proxy's Discretion	Total	Abstain	Exclusions
1.	S	3,148,961	38,000	9,918	3,196,879	4,623	7,113,869
		98.50%	1.19%	0.31%	100%		
2.	S	10,305,853	-	9,518	10,315,371	-	-
		99.91%	-	0.09%	100%		
3.	S	10,299,453	6,000	9,918	10,315,371	-	-
		99.85%	0.06%	0.10%	100%		
4.	S	9,776,853	6,000	9,518	9,792,371	523,000	-
		99.85%	0.06%	0.10%	100%		
5.	S	10,305,453	-	9,918	10,315,371	-	-
		99.90%	-	0.10%	100%		
6.	S	6,596,938	356,514	9,918	6,963,370	198,645	3,153,356
		94.74%	5.12%	0.14%	100%		
7.	S	5,663,826	356,514	9,518	6,029,858	525,000	3,760,513
		93.93%	5.91%	0.16%	100%		
8.	S	9,752,939	350,514	9,918	10,113,371	2,000	200,000
		96.44%	3.46%	0.10%	100%		
9.	S	10,041,853	262,000	9,518	10,313,371	2,000	-
		97.37%	2.54%	0.09%	100%		
10.	S	10,299,453	-	9,918	10,309,371	6,000	-
		99.90%	-	0.10%	100%		
11.	S	10,290,453	13,000	9,918	10,313,371	2,000	-
		99.78%	0.12%	0.10%	100%		



About Invex Therapeutics Ltd

Invex (ASX:IXC) is an ASX listed biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. www.invextherapeutics.com

Exenatide

- Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which received approval in the US and Europe for the treatment of type 2 diabetes in 2005 and 2006 respectively.
- Professor Alexandra Sinclair's research showed that GLP-1 receptors are expressed in the choroid plexus in the brain and that Exenatide can bind to these receptors and reduce secretion of cerebrospinal fluid.
- Current Exenatide dosage forms are not optimised for IIH.

Idiopathic Intracranial Hypertension (IIH)

- IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve, causing permanent vision loss in 25% of those affected.
- The usual age of onset is 20-30 years, and it is most common in women who are obese.
- IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.